MENS
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
The negative P/B ratio indicates the company's liabilities exceed its assets.
- Price/Book is -8.91
- No earnings for P/E calculation
- No Graham Number available
Future viability is entirely speculative without a revenue stream.
- Biotech sector potential
- No revenue growth data
- No earnings growth data
- Lack of analyst coverage
Historical price action shows a total collapse of investor confidence.
- 95% decline in 6 months
- 72.4% decline over 1-5 years
- Crash from 52-week high of $67.00
Piotroski score of 2 indicates very weak financial health; Current Ratio < 1.0 suggests inability to cover short-term debts.
- Piotroski F-Score 2/9
- Current Ratio 0.62
- ROA -5.44%
Company is in no position to return capital to shareholders.
- Zero dividend yield
- Zero payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for MENS and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
MENS
Jyong Biotech Ltd.
Primary
|
-72.4% | -72.4% | -72.4% | -95.0% | +40.9% | +13.0% |
|
LUCD
Lucid Diagnostics Inc.
Peer
|
-89.1% | -5.9% | +7.6% | +8.5% | -6.6% | +13.3% |
|
HITI
High Tide Inc.
Peer
|
-71.8% | +84.9% | +18.3% | -32.1% | -5.7% | +0.9% |
|
ANIK
Anika Therapeutics, Inc.
Peer
|
-62.2% | -47.2% | -6.6% | +63.8% | +38.5% | +0.6% |
|
CVRX
CVRx, Inc.
Peer
|
-70.1% | -7.4% | -27.5% | -4.1% | +6.5% | -11.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2024
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
MENS
Jyong Biotech Ltd.
|
BEARISH | $212.12M | - | -% | -% | $2.79 | |
|
LUCD
Lucid Diagnostics Inc.
|
BEARISH | $218.06M | - | -710.6% | -% | $1.28 | Compare |
|
HITI
High Tide Inc.
|
BEARISH | $204.8M | - | -39.7% | -7.4% | $2.33 | Compare |
|
ANIK
Anika Therapeutics, Inc.
|
BEARISH | $204.78M | - | -6.7% | -9.6% | $14.2 | Compare |
|
CVRX
CVRx, Inc.
|
BEARISH | $220.23M | - | -96.6% | -94.1% | $8.37 | Compare |
Past News Coverage
Recent headlines mentioning MENS from our newsroom.